Amoxicillin and Imfinzi drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Amoxicillin (amoxicillin) and Imfinzi (durvalumab). Common drug interactions include diabetic ketoacidosis among females and agranulocytosis among males.

The phase IV clinical study analyzes what interactions people have when they take Amoxicillin and Imfinzi. It is created by eHealthMe based on reports of 11 people who take the same drugs from the FDA, and is updated regularly.

What is Amoxicillin?

Amoxicillin has active ingredients of amoxicillin. It is often used in infection. eHealthMe is studying from 99,235 Amoxicillin users. Check the latest studies of Amoxicillin.

What is Imfinzi?

Imfinzi has active ingredients of durvalumab. eHealthMe is studying from 8,353 Imfinzi users. Check the latest studies of Imfinzi.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 29, 2026

11 people who take Amoxicillin and Imfinzi together, and have interactions are studied.

Amoxicillin and Imfinzi drug interactions.

What are the common drug interactions of Amoxicillin and Imfinzi, by gender? *:

female:

Diabetic ketoacidosis (diabetic ketoacidosis (dka) is high concentrations of ketone bodies)

male:

Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection)
Anger
Dizziness
Dry skin
Dyspnoea (difficult or laboured respiration)
Fatigue (feeling of tiredness)
Fear
Headache (pain in head)
Influenza
Malaise (a feeling of general discomfort or uneasiness)

What are the common drug interactions of Amoxicillin and Imfinzi, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

Rash

60+:

Diabetic ketoacidosis (diabetic ketoacidosis (dka) is high concentrations of ketone bodies)
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection)
Biliary obstruction
Cholangitis (infection of the bile duct)
Drug eruption (adverse drug reaction of the skin)
Parotitis (inflammation of a parotid gland)
Sepsis (a severe blood infection that can lead to organ failure and death)
Skin disorder (skin disease)

What are the existing conditions these people have? *

Lung Neoplasm Malignant (cancer tumour of lung): 3 people, 27.27%
Lung Disorder (lung disease): 3 people, 27.27%
Insomnia (sleeplessness): 3 people, 27.27%
Colitis (inflammation of colon): 3 people, 27.27%
Bronchial Carcinoma (lung cancer): 3 people, 27.27%
Renal Cell Carcinoma (a kidney cancer): 1 person, 9.09%
Non-Small Cell Lung Cancer Stage Iii: 1 person, 9.09%
Lung Cancer - Non-Small Cell (lung cancer): 1 person, 9.09%
Cholangitis (infection of the bile duct): 1 person, 9.09%
Cholangiocarcinoma (a cancer that forms glands or secretes significant amounts of mucins): 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Amoxicillin and Imfinzi?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously